Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SeaBeEYE

Financiado

A BREAKTHROUGH TECHNOLOGY DESIGNED TO PRESERVE SIGHT AND HALTING VISION LOSS ASS...

A BREAKTHROUGH TECHNOLOGY DESIGNED TO PRESERVE SIGHT AND HALTING VISION LOSS ASSOCIATED WITH A RANGE OF RETINAL DISEASE BY PREVENTING THE DEATH OF KEY RETINAL CELLS . I am the CEO and Cofounder of SeaBeLife, a French biotechnology company developing First-In-Class drugs to treat severe pathologies affecting our vital organs for which there are no effective treatments. We develop an innovative t... ver más

30/06/2024

SEABELIFE BIOTECH

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

SEABELIFE SAS No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU ExpectedOutcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

SEABELIFE BIOTECH

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-122807OB-C32 TERAPIA CON CELULAS FOTORRECEPTORAS PARA LA REGENERACION DE... 189K€ Cerrado

SAF2010-21317 ESTRATEGIAS DE RESCATE Y REGENERACION PARA EL TRATAMIENTO DE... 55K€ Cerrado

CNS2023-144390 Fisiopatología de órganos y sistemas 200K€ Cerrado

SAF2016-75681-R ALTERACIONES MOLECULARES Y CELULARES TEMPRANAS EN RETINOSIS... 200K€ Cerrado

SAF2013-41059-R ESTRATEGIAS NEUROPROTECTORAS PARA LA RETINOSIS PIGMENTARIA B... 357K€ Cerrado

EIN2019-103021 MODELADO DE UNA RETINA ARTIFICIAL MEDIANTE CELULAS Y TEJIDOS... 12K€ Cerrado

Duración del proyecto: 12 meses Fecha Inicio: 2023-06-28
Fecha Fin: 2024-06-30

Líder del proyecto

SEABELIFE SAS No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto I am the CEO and Cofounder of SeaBeLife, a French biotechnology company developing First-In-Class drugs to treat severe pathologies affecting our vital organs for which there are no effective treatments. We develop an innovative therapeutic approach protected by 4 patents and with a lead program to treat Acute Liver Failure and a second program to preserve sight and halting vision loss associated with a range of retinal disease by preventing the death of key retinal cells. We are developing a first-in-class drug based on a dual-targeted approach, capable of stopping directly and simultaneously two forms of regulated cell death pathways known to be involved in triggering of numerous acute and chronic pathologies and contributing to organ damage. Our molecule protects the cells, prevents tissue damage, and finally preserves and restores organ function. SeaBeLife is the only company worldwide developing such a therapeutic approach. Our molecule has a direct protective effect on cells and has the potential to prevent evolution to severe life-threatening form. We have already obtained very convincing in vivo results in several highly predictive models. Our molecules were tested on pharmacologically relevant murine models and have shown no toxicity and strong efficacy. SeaBeLife is composed of an experienced and complementary operational team managing by two women and supported by a scientific and strategic advisory board with scientific and medical experts of extensive expertise in drug development. We have already raised 4.3M€ to develop our technology and we are ready to bring our molecules to the clinic and validate its safety and efficacy. The main milestones over the next 2 years will be the production of compliant clinical batches and the realization of phase 1 and phase 2a clinical trials. The WomenTechEU award and funding will allow us to gain visibility as women entrepreneurs and also to take an important step in our pre-clinical development for eye diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores